TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (TRACERx)
Robert Hynds, PhD, UCL, London, UK, talks on the TRACERx (NCT01888601) study aiming to characterize tumor heterogeneity in a cohort of patients with non-small cell lung cancer (NSCLC). Dr Hynds provides an overview of his role in TRACERx involving the development of patient-derived xenograft (PDX) models derived from multiple regions of primary NSCLC from patients in lung TRACERx to assess the fidelity of PDX models as a surrogate for the patientsโ tumor. https://www.biorxiv.org/conten....t/10.1101/2023.01.06 This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found